Diabetes
Jul 16, 2024
Immutep’ First-Line Treatment Positive Outcomes; Pfizer’s Once-Daily Oral GLP-1 Agonist Danuglipron; FDA Issues Complete Response Letter to Novo Nordisk; Arcutis’ ZORYVE® Cream 0.15% FDA Approval; NICE Recommends Ebglyss For Moderate To Severe Atopic Dermatitis
Immutep Announces Promising Outcomes for First-Line Treatment in PD-L1 Negative Head and Neck Squamous Cell Carcinoma Patients Immutep Limited announced positive results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial, evaluating eftilagimod alfa (efti) combined with MSD’s anti-PD-1 therapy KEYTR...
Read More...
Jun 25, 2024
Alnylam’s HELIOS-B Phase III Study of Vutrisiran; Bristol Myers Squibb Secures FDA Nod for KRAZATI and Cetuximab; Daichii Sankyo’s EZHARMIA® Receives Japan Approval; Vertex’s Phase I/II VX-880 Trial; argenx’s VYVGART Hytrulo FDA Approval
Alnylam's HELIOS-B Phase III Study of Vutrisiran Shows Positive Results, Meeting All Primary and Secondary Endpoints Alnylam Pharmaceuticals, Inc. reported encouraging topline outcomes from its HELIOS-B Phase III study of vutrisiran, an experimental RNAi therapy being developed to treat ATTR amyloidosis with car...
Read More...
Apr 03, 2024
Nutrition Nexus: Illuminating the Growth Trajectory Path in the Dietary Supplements Market
The Dietary Supplements market has experienced significant growth over the past years, driven by a variety of factors contributing to its sustained demand. One primary reason for this surge is the increasing awareness and emphasis on preventive healthcare and wellness among consumers worldwide. As people become mor...
Read More...
Dec 25, 2023
Future Avenues for Prediabetes Treatment: The Road Ahead
Prediabetes is a significant health concern characterized by elevated blood sugar levels that fall between the normal range and the diagnostic threshold for type 2 diabetes. Often labeled as borderline diabetes, this metabolic condition is intricately linked to the global rise in obesity and poses an escalating wor...
Read More...
Dec 05, 2023
FDA Grants Priority Review to Merck’s Application for KEYTRUDA Plus Padcev; Roche and Carmot Therapeutics’s Definitive Merger Agreement; AbbVie to Acquire ImmunoGen; FDA Grants Orphan Drug Designation to LP-284; Merck Announces Commercialization Agreement With Abbisko; Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial
FDA Grants Priority Review to Merck’s Application for KEYTRUDA Plus Padcev for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer Merck, operating as MSD internationally, reported that the U.S. Food and Drug Administration (FDA) has prioritized the review of a supplementar...
Read More...
Oct 25, 2023
Charting the Growth of the Insulin Pens Market Amidst Rising Demand
The evolution of technology has been a driving force behind the remarkable growth of the Insulin Pens market. Insulin Pens, from their inception as relatively basic delivery devices, have undergone a substantial transformation, becoming highly advanced and user-friendly tools. In the early stages, these pens requir...
Read More...
Sep 28, 2023
Orthofix Launched the Galaxy Fixation Gemini System; Oxford Biodynamics Launched the EpiSwitch Prostate Screening Blood Test; CE Mark for the Medtronic’s New Simplera CGM; FDA 510(k) Clearance to MicroVention’s SOFIA™ EX 5F 115cm; SHL Telemedicine’s SmartHeart® Technology; Cardiosense’s Nationwide Heart Failure Study
Orthofix Launched the Galaxy Fixation Gemini System and Expanded Sterile Kit Offerings for Orthopedic Trauma Procedures On September 20, 2023, Orthofix Medical Inc., a leading global spine and orthopedics company, launched the Galaxy Fixation Gemini™ system. It is a stable external fixation system that ...
Read More...
May 01, 2023
Cell and Gene Therapies for Diabetes Treatment: A Permanent Cure for Patients?
Diabetes is the 8th largest cause of death in the United States (although its prevalence may be underreported). Diabetes affects more than 37 million people in the United States, and 1 in every 5 are unaware of their condition. Over 96 million US adults—more than one-third—have prediabetes, and more than 8 out of 1...
Read More...
Jan 26, 2023
Tandem Acquires AMF Medical; NeuroMetrix Launched DPNCheck 2.0 Device; FDA Approves Cytovale’s IntelliSep Sepsis Test; FDA Clearance for the Ø 4.5mm VADER Pedicle Screws; Pie Medical Imaging’s vFFR FASTIII Trial; Hip Innovation Technology Announced Initiation Investigational Device Exemption Study
Tandem Diabetes Care Completed Acquisition of the Insulin Patch Pump Developer, AMF Medical On January 23, 2023, Tandem Diabetes Care, Inc., a global insulin delivery and diabetes technology company, announced the complete acquisition of AMF Medical SA, the privately held Swiss developer of the SigiTM Patch Pump...
Read More...
Dec 01, 2022
AnchorDx’s UriFind Bladder Cancer Assay in the US; UroMems Initiates Smart Implant to Treat Stress Urinary Incontinence; FDA 510(k) Clearance to NeuroLogica’s BodyTom 64; CE-IVD Mark Approval to SeekInCure’s Recurrence Monitoring Kit Gets; Ypsomed and CamDiab’s Automated Insulin Dosing System; Boston Scientific to Acquire Apollo Endosurgery
AnchorDx Clinical Trial Enrols First Patient for its UriFind® Bladder Cancer Assay in the US On November 23, 2022, AnchorDx, announced the first patient enrollment for its clinical trials of the UriFind® bladder cancer assay in the United States. The UriFind® bladder cancer assay clinical trial in the U...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
